Chimerix, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMRX research report →
Companywww.chimerix.com
Chimerix, Inc. , a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
- CEO
- Michael T. Andriole
- IPO
- 2013
- Employees
- 79
- HQ
- Durham, NC, US
Price Chart
Valuation
- Market Cap
- $801.08M
- P/E
- -8.67
- P/S
- 3778.70
- P/B
- 6.30
- EV/EBITDA
- -7.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -45550.47%
- Net Margin
- -41691.98%
- ROE
- -56.17%
- ROIC
- -79.06%
Growth & Income
- Revenue
- $212.00K · -34.57%
- Net Income
- $-88,387,000 · -7.66%
- EPS
- $-0.99 · -6.45%
- Op Income
- $-96,567,000
- FCF YoY
- -8.80%
Performance & Tape
- 52W High
- $8.55
- 52W Low
- $0.75
- 50D MA
- $6.67
- 200D MA
- $2.75
- Beta
- -0.18
- Avg Volume
- 4.05M
Get TickerSpark's AI analysis on CMRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 21, 25 | Vakiener Victoria | sell | 60,000 |
| Apr 21, 25 | Vakiener Victoria | sell | 60,000 |
| Apr 21, 25 | Vakiener Victoria | sell | 35,000 |
| Apr 21, 25 | Vakiener Victoria | sell | 50,000 |
| Apr 21, 25 | Vakiener Victoria | sell | 60,000 |
| Apr 21, 25 | Sherman Michael A. | sell | 233,413 |
| Apr 21, 25 | Sherman Michael A. | sell | 60,000 |
| Apr 21, 25 | Sherman Michael A. | sell | 1,150,000 |
| Apr 21, 25 | Sherman Michael A. | sell | 632,500 |
| Apr 21, 25 | Sherman Michael A. | sell | 700,000 |
Our CMRX Coverage
We haven't published any research on CMRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CMRX Report →